The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Pre-treatment ctDNA levels significantly predicts OS and PFS in NADIM II
The Phase II NADIM II trial (NCT03838159) was designed to explore neoadjuvant nivolumab plus chemotherapy versus chemotherapy alone in patients with locally advanced and potentially resectable non-small cell lung cancer (NSCLC). Atocha Romero, PharmD, PhD, Hospital Universitario Puerta de Hierro, Madrid, Spain, talks on an analysis of circulating tumor DNA (ctDNA) from the pre-treatment plasma samples of patients enrolled in the NADIM II trial. Baseline ctDNA was detected in 52 of 54 pre-treatment samples and were significantly associated with tumor size. Pre-treatment ctDNA levels were significantly associated with progression-free survival (PFS) and overall-survival (OS). Overall, baseline ctDNA evidently identified patients at high risk of progression or death and may therefore be utilized to tailor subsequent treatment. Additionally, ctDNA was significantly associated with tumor size. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
Transcript
We think that circulating tumor DNA is good analyte to monitor tumor response to treatment. In NADIM I, the first trial, we already saw that circulating tumor DNA levels correlated well with tumor response. It predicted survival as good as pathological complete response or even better, the capacity to predict survival outcome was even better than imagined techniques. And so here we wanted to do the same with NADIM II...
We think that circulating tumor DNA is good analyte to monitor tumor response to treatment. In NADIM I, the first trial, we already saw that circulating tumor DNA levels correlated well with tumor response. It predicted survival as good as pathological complete response or even better, the capacity to predict survival outcome was even better than imagined techniques. And so here we wanted to do the same with NADIM II. We wanted to validate these results and what I am presenting now is that pretreatment circulating tumor DNA levels correlates well with survival, indicating that this is a good prognostic factor, and it may be used for stratify patients and identify those that are at high risk of progression and death, because they have a high tumor load. And we also have found that circulating tumor DNA correlates well with tumor size in these patients. There is a significant association with circulating tumor DNA levels and tumor size.
Read more...
